X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Natoli NP-RD30 Included at Diosna ProcessLab

Content Team by Content Team
21st September 2020
in Drug Development, News
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The Diosna Dierks & Söhne GmbH recently opened the “Diosna ProcessLab” located in Osnabrück, Germany. The lab, which was completed in April 2020, offers research and formulation trials as well as virtual and in-person training classes. It offers an overview of the different system options and various possibilities for experimental implementation.

The NP-RD30 Rotary Tablet Press

One of the systems included in the Diosna ProcessLab is the Natoli NP-RD30, which is designed to help solve formulation and scale-up challenges. The multi-functional rotary tablet press replicates the design and functionality of a full-scale production press with the analytical capabilities of an R&D machine.

The NP-RD30 helps to get products to market faster with the data acquisition, analysis, and scalability features included in its user-friendly interface. The NP-RD30 is 21 CFR Part 11 compliant. It comes with an intuitive 21” HMI touchscreen and USB port for data transfer. Rolling casters allow for easy mobility of the machine. The NP-RD30 is equipped with an integrated duel vacuum system, a built-in calibration tool, upper and lower punch seals, powder recirculation system, and self-adjusting lower punch retainers with an exclusive push button feature.

Efficient and Dependable

An optimized fast-fill cam design creates a vacuum to assist in die filling for more consistent tablet weights. The NP-RD30 is designed with same diameter pre- and main compression rollers, independent overload, ejection, and take-off force monitoring. While designed to meet the needs of research and development, the NP-RD30 can also be used as a small batch production press with efficient and dependable standard batch reporting.

The NP-RD30 will be used to help enable the complete production of tablets for seminars, training, and more. The tablet press completes the manufacturing process chain at the Diosna ProcessLab that starts with powder mixing, granulation, final blending, tableting (completed with the NP-RD30), and finally, coating of the tablets. Customers who perform formulation trials at Diosna ProcessLab, are able to compress the granules to tablets, getting the opportunity to handle and analyze the quality of the final tablet with all its physical and chemical characteristics.

The first seminar in the new Diosna ProcessLab, “PTS-Seminar: Intensive Training Wet Granulation,” is planned for October 28-29, 2020 depending on availability of the Diosna ProcessLab due to current global circumstances. The number of attendees has been reduced to provide a safe environment in accordance with the Good Manufacturing Practice (GMP) standards with the World Health Organization (WHO). The Diosna ProcessLab and the equipment was also built according to GMP standards.

Previous Post

OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics

Next Post

DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

DCGI nod to Serum-Oxford covid-19 vaccine for phase 2, 3 clinical trials in India

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In